Novo Nordisk A/S - share repurchase programme
September 09 2024 - 10:10AM
UK Regulatory
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 9 September 2024 – On 7
August 2024, Novo Nordisk initiated a share repurchase programme in
accordance with Article 5 of Regulation No 596/2014 of the European
Parliament and Council of 16 April 2014 (MAR) and the Commission
Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe
Harbour Rules"). This programme is part of the overall share
repurchase programme of up to DKK 20 billion to be executed during
a 12-month period beginning 6 February 2024.
Under the programme initiated 7 August 2024, Novo Nordisk will
repurchase B shares for an amount up to DKK 2.4 billion in the
period from 7 August 2024 to 4 November 2024.
Since 2 September 2024, the following transactions have been
made:
|
|
Number of
B shares |
Average
purchase price |
Transaction
value, DKK |
|
Accumulated, last announcement |
744,187 |
|
671,844,599 |
| 2 September
2024 |
45,000 |
925.37 |
41,641,843 |
| 3 September
2024 |
41,000 |
933.58 |
38,276,681 |
| 4 September
2024 |
43,000 |
905.99 |
38,957,720 |
| 5 September
2024 |
41,000 |
893.85 |
36,648,039 |
| 6 September
2024 |
42,000 |
885.28 |
37,181,588 |
|
Accumulated under the programme |
956,187 |
|
864,550,471 |
The details for each transaction made under the share repurchase
programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of
13,351,944 B shares of DKK 0.10 as treasury shares, corresponding
to 0.3% of the share capital. The total amount of A and B shares in
the company is 4,465,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to
DKK 20 billion during a 12-month period beginning 6 February 2024.
As of 6 September 2024, Novo Nordisk has since 6 February 2024
repurchased a total of 12,023,313 B shares at an average share
price of DKK 880.98 per B share equal to a transaction value of DKK
10,592,256,521.
Novo Nordisk is a leading global healthcare company, founded
in 1923 and headquartered in Denmark. Our purpose is to drive
change to defeat serious chronic diseases, built upon our heritage
in diabetes. We do so by pioneering scientific breakthroughs,
expanding access to our medicines, and working to prevent and
ultimately cure disease. Novo Nordisk employs about 69,000 people
in 80 countries and markets its products in around 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com,
Facebook, Instagram,
X, LinkedIn and
YouTube.
Contact for further information.
|
Media: |
|
Ambre
James-Brown
+45 3079 9289
abmo@novonordisk.com
|
Liz
Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com
|
|
Investors: |
|
Jacob
Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com
|
David
Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com
|
Mark
Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com
|
Sina
Meyer
+45 3079 6656
azey@novonordisk.com
|
Frederik
Taylor Pitter
+45 3075 8259
fptr@novonordisk.com |
Ida
Schaap Melvold
+45 3077 5649 idmg@novonordisk.com |
Company announcement No 69/2024
- CA20240909 Safe Harbour
- CA20240909 safe harbour transaction details
Novo Nordisk (TG:NOV)
Historical Stock Chart
From Oct 2024 to Nov 2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
From Nov 2023 to Nov 2024
